Methods and compositions for treatment of Zika virus infection
Disclosed are 9-deazaaadenine derivatives of the general formula (I) and pharmaceutically acceptable salts thereof, wherein A is OH or NH 2 , and B is H or NH 2 . Methods for treating and/or suppressing a Zika virus infection with the compounds disclosed are also provided. Pharmaceutical compositions comprising the disclosed compounds are also provided. Such pharmaceutical compositions may optionally contain one or more additional active agents.
1. A method of treating or suppressing a disease or condition associated with a Zika virus infection in a subject, the method comprising the step of administering to the subject an effective amount of a compound of the formula I or a pharmaceutically acceptable salt, hydrate or solvate thereof
wherein A is OH or NH 2 , and B is H or NH 2 , wherein the disease or condition is Guillain-Barré syndrome.
2. The method of claim 1 , wherein A is NH 2 and B is H.
3. The method of claim 1 , wherein the disease or condition is Guillain-Barré syndrome and at least one of fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, headache, neurological complications, or auto-immune complications.
4. The method of claim 1 , wherein a single dose of the compound of formula I is administered during a course of treatment.
5. The method of claim 4 , wherein the single dose is administered in a single administration or in multiple administrations.
6. The method of claim 1 , wherein more than one dose of the compound of formula I is administered during a course of treatment.
7. The method of claim 6 , wherein each dose is administered in a single administration or in multiple administrations.
8. The method of claim 7 , wherein the amount of the compound of the formula I in each dose is not the same.
9. The method of claim 6 , wherein the course of treatment comprises administering at least one dose as a loading dose and at least one dose as a maintenance dose.
10. The method of claim 1 , wherein the compound of formula I is administered by intravenous administration, intramuscular administration, parenteral administration, oral administration or a combination of the foregoing.
11. The method of claim 1 , wherein the compound of formula I is administered as a pharmaceutical composition comprising the compound of formula I and a pharmaceutically acceptable carrier.
12. The method of claim 2 , wherein the compound of formula I is administered as a pharmaceutical composition comprising the compound of formula I and a pharmaceutically acceptable carrier.